- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
JPMorgan Chase Boosts Stake in GRAIL, Inc.
Institutional investor increases holdings in biotech firm by over 159% in Q3
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
JPMorgan Chase & Co. significantly increased its stake in GRAIL, Inc. (NASDAQ:GRAL) during the third quarter of 2026, boosting its holdings by 159.1% according to a recent SEC filing. The institutional investor now owns 206,120 shares of the biotech company's stock, worth approximately $12.2 million.
Why it matters
GRAIL is a prominent player in the emerging field of early cancer detection through blood tests, an area that has seen significant investment and innovation in recent years. JPMorgan's increased stake suggests the financial institution sees strong potential in GRAIL's technology and business prospects.
The details
According to the 13F filing, JPMorgan Chase acquired an additional 126,576 shares of GRAIL in Q3 2026, bringing its total holdings to 206,120 shares. This represents about 0.57% of GRAIL's outstanding stock. Other major institutional investors in GRAIL include Geode Capital Management, Allianz Asset Management, and Invesco Ltd., all of which have also boosted their positions in the company over the past year.
- JPMorgan Chase filed the 13F report disclosing the increased GRAIL stake on March 6, 2026.
- The Q3 2026 period covered in the 13F filing ran from July 1 to September 30, 2026.
The players
JPMorgan Chase & Co.
A multinational investment bank and financial services company headquartered in New York City.
GRAIL, Inc.
A biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test, leveraging advances in genomics and machine learning.
The takeaway
JPMorgan Chase's increased investment in GRAIL underscores the growing interest and optimism around the company's pioneering work in early cancer detection. As the field of liquid biopsy continues to advance, GRAIL's technology could play a pivotal role in transforming cancer screening and treatment.
